Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy
of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor
after progression on standard treatment.